BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 26, 2009
 |  BioCentury  |  Product Development

RhoKing Glaucoma

Although its AR-12286 is not the most advanced Rho kinase inhibitor in the increasingly crowded glaucoma space, Aerie Pharmaceuticals Inc. believes the compound's potency and specificity will allow it to compete. Last week, the biotech announced top line data from a Phase IIa trial in which AR-12286 showed a favorable effect on intraocular pressure.

In the U.S. double-blind study in 88 patients, patients were given AR-12286 or sham eye drop once in the morning, once at night, or twice a day. Each dosing regime was administered for one week for a total of three weeks. Intraocular pressure (IOP) was measured for each dosing regime. No serious side effects were reported.

The maximum change in mean intraocular pressure (IOP) from baseline was 28% for the 0.25% solution of AR-12286 dosed twice daily. The company has not disclosed the p-value, but said the mean change from baseline was statistically significant for...

Read the full 736 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >